WO2023078868 - CRYSTALLINE FORMS OF A MONOACYLGLYCEROL LIPASE INHIBITOR
National phase entry:
Publication Number
WO/2023/078868
Publication Date
11.05.2023
International Application No.
PCT/EP2022/080434
International Filing Date
01.11.2022
Title **
[English]
CRYSTALLINE FORMS OF A MONOACYLGLYCEROL LIPASE INHIBITOR
[French]
FORMES CRISTALLINES D'UN INHIBITEUR DE MONOACYLGLYCÉROL LIPASE
Applicants **
H. LUNDBECK A/S
Inventors
ANDREW, Samuel George
CINCOTTI, Antonio
PATTERSON, Adam Ross
EDWARDS, Richard James
VETTER, Thomas
JUHL, Martin
LOPEZ DE DIEGO, Heidi
GRICE, Cheryl A.
WIENER, John J.M.
BUZARD, Daniel J.
ALLAN, Amy
GANCEDO, Susana Del Rio
Priority Data
63/274,887
02.11.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2318 | |
| EPO | Filing, Examination, Granting | 9645 | |
| Japan | Filing, Examination, Granting | 2212 | |
| South Korea | Filing, Examination, Granting | 2105 | |
| USA | Filing, Examination, Granting | 7140 |
Total:
23,420
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Described herein is new crystalline forms of the MAGL inhibitor 1-(1-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)-1,8-diazaspiro[4.5]decane-8-carbonyl)-1H-pyrazole-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.[French]
L'invention concerne de nouvelles formes cristallines de l'inhibiteur de MAGL 1-(1-(2-(pyrrolidin-1-yl)-4-(trifluorométhyl)benzyl)-1,8-diazaspiro[4,5]décane-8-carbonyl)-1H-pyrazole-3-carboxylique, ou d'un sel pharmaceutiquement acceptable de celui-ci.